OUP user menu

Journal of Crohn's and Colitis: 9 (12)


Laurence J. Egan, Ireland

Associate Editors

Maria T. Abreu, USAShomron Ben-Horin, IsraelSilvio Danese, ItalyPeter Lakatos, HungaryMiles Parkes, UKGijs van den Brink, NLSéverine Vermeire, Belgium


Published on behalf of

Tolerability of one hour 10 mg/kg infliximab infusions in patients with inflammatory bowel disease

Abdenour Babouri, Anthony Buisson, Marc-André Bigard, Laurent Peyrin-Biroulet
DOI: http://dx.doi.org/10.1016/j.crohns.2012.03.007 129-133 First published online: 1 March 2013


Background and aim: In patients with inflammatory bowel disease (IBD) tolerating 2-h infusions of 5 mg/kg infliximab scheduled maintenance therapy, the infusion time can be shortened to 1-h with good tolerability. The tolerability of one 1-hour 10 mg/kg infliximab infusion in patients with IBD is unknown.

Methods: Between August and September 2011, 8 patients received one 1-hour 10 mg/kg infliximab infusion. All patients were treated in our infusion unit under standard operating procedures. Intravenous steroid premedication was given to all patients. These 8 patients were compared to 26 IBD patients who received one 1-hour 5 mg/kg infliximab infusion during the same study period at Nancy University Hospital. The charts of these 34 patients were reviewed to assess tolerability of 1-hour infliximab infusions.

Results: A total of 34 patients with IBD on infliximab maintenance therapy (82.4% Crohn's disease, 17.6% ulcerative colitis; 22 females) received one 1-hour 5 or 10 mg/kg infusion. Four patients were receiving concomitant immunomodulators. No severe infusions reactions were reported in the 34 IBD patients. Two mild acute reactions (7.7%) and two delayed reactions (7.7%) occurred in the 5 mg/kg infliximab group. We did not observe any acute or delayed infliximab reactions in the 10 mg/kg patients group.

Conclusions: In patients with inflammatory bowel disease receiving infliximab scheduled maintenance therapy, 1-hour infusion time for 10 mg/kg infliximab appears to be well tolerated. Large prospective studies are needed to confirm our findings.

  • Infliximab
  • One hour infusions
  • Inflammatory bowel disease
  • Acute reactions
  • Delayed reactions
View Full Text

Log in through your institution